Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
Open Access
- 1 August 2007
- journal article
- Published by Elsevier BV in Journal of Lipid Research
- Vol. 48 (8), 1763-1771
- https://doi.org/10.1194/jlr.m700108-jlr200
Abstract
In addition to efficiently decreasing VLDL-triglycerides (TGs), fenofibrate increases HDL-cholesterol levels in humans. We investigated whether the fenofibrate-induced increase in HDL-cholesterol is dependent on the expression of the cholesteryl ester transfer protein (CETP). To this end, APOE*3-Leiden (E3L) transgenic mice without and with the human CETP transgene, under the control of its natural regulatory flanking regions, were fed a Western-type diet with or without fenofibrate. Fenofibrate (0.04% in the diet) decreased plasma TG in E3L and E3L.CETP mice (−59% and −60%; P < 0.001), caused by a strong reduction in VLDL. Whereas fenofibrate did not affect HDL-cholesterol in E3L mice, fenofibrate dose-dependently increased HDL-cholesterol in E3L.CETP mice (up to +91%). Fenofibrate did not affect the turnover of HDL-cholesteryl ester (CE), indicating that fenofibrate causes a higher steady-state HDL-cholesterol level without altering the HDL-cholesterol flux through plasma. Analysis of the hepatic gene expression profile showed that fenofibrate did not differentially affect the main players in HDL metabolism in E3L.CETP mice compared with E3L mice. However, in E3L.CETP mice, fenofibrate reduced hepatic CETP mRNA (−72%; P < 0.01) as well as the CE transfer activity in plasma (−73%; P < 0.01). We conclude that fenofibrate increases HDL-cholesterol by reducing the CETP-dependent transfer of cholesterol from HDL to (V)LDL, as related to lower hepatic CETP expression and a reduced plasma (V)LDL pool.Keywords
This publication has 61 references indexed in Scilit:
- The Failure of TorcetrapibArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Effectiveness of Inhibition of Cholesteryl Ester Transfer Protein by JTT-705 in Combination With Pravastatin in Type II DyslipidemiaThe American Journal of Cardiology, 2005
- Lipid transfer proteins (LTP) and atherosclerosisAtherosclerosis, 2005
- The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiationBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined HyperlipidemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.JCI Insight, 1996
- Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.JCI Insight, 1995
- Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.JCI Insight, 1994
- Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemiaAtherosclerosis, 1986
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959